Streptomyces isolates

Last updated

Streptomyces isolates have yielded the majority of human, animal, and agricultural antibiotics, as well as a number of fundamental chemotherapy medicines. Streptomyces is the largest antibiotic-producing genus of Actinomycetota, producing chemotherapy, antibacterial, antifungal, antiparasitic drugs, and immunosuppressants. [1] Streptomyces isolates are typically initiated with the aerial hyphal formation from the mycelium. [2]

Contents

Anticancer medicines

Doxorubicin intercalating DNA. Doxorubicin-DNA complex 1D12.png
Doxorubicin intercalating DNA.

Streptomyces, yielded the medicines doxorubicin (Doxil), daunorubicin (DaunoXome), and streptozotocin (Zanosar). Doxorubicin is the precursor to valrubicin (Valstar), myocet, and pirarubicin. Daunorubicin is the precursor to idarubicin (Idamycin), epirubicin (Ellence), and zorubicin.[ citation needed ]

Streptomyces is the original source of dactinomycin (Cosmegen), bleomycin (Blenoxane), pingyangmycin (Bleomycin A5), mitomycin C (Mutamycin), rebeccamycin, staurosporine (precursor to stauprimide and midostaurin), neothramycin, aclarubicin, tomaymycin, sibiromycin, and mazethramycin.[ citation needed ]

Derivatives of Streptomycetes isolate migrastatin, including isomigrastatin, dorrigocin A & B, and the synthetic derivative macroketone, are being researched for anticancer activity.[ citation needed ]

Antibiotics

Most clinical antibiotics were found during the "golden age of antibiotics" (1940s–1960s). Actinomycin was the first antibiotic isolated from Streptomyces in 1940, followed by streptomycin three years later. Antibiotics from Streptomyces isolates (including various aminoglycosides) would go on to comprise over two-thirds of all marketed antibiotics.[ citation needed ]

Streptomyces-derived antibiotics include:

Clavulanic acid ( Streptomyces clavuligerus ) is used in combination with some antibiotics (such as amoxicillin) to weaken bacterial-resistance. Novel anti-infectives being developed include the guadinomines (from Streptomyces sp. K01-0509), [14] inhibitors of the type III secretion system.

Non-Streptomyces actinomycetes, filamentous fungi, and non-filamentous bacteria, have also yielded important antibiotics.[ citation needed ]

Antifungals

Nystatin ( Streptomyces noursei ), amphotericin B ( Streptomyces nodosus ), ossamycin ( Streptomyces hygroscopicus ), and natamycin ( Streptomyces natalensis ) are antifungals isolated from Streptomyces.[ citation needed ]

Immunosuppressants

Sirolimus (Rapamycin), ascomycin, and tacrolimus were isolated from Streptomyces. Pimecrolimus is a derivative of ascomycin. Ubenimex is derived from S. olivoreticuli. [15]

Antiparasitics

Streptomyces avermitilis synthesizes the antiparasitic ivermectin (Stromectol). Other antiparasitics made by Streptomyces include, milbemycin oxime, moxidectin, and milbemycin.[ citation needed ]

Biotechnology

Biosynthesis of sirolimus Domain organization of PKS of rapamycin and biosynthetic intermediates.svg
Biosynthesis of sirolimus

Traditionally, Escherichia coli is the choice bacterium to express eukaryotic and recombinant genes. E. coli is well understood and has a successful track record producing insulin, the artemisinin precursor artemisinic acid, and filgrastim (Neupogen). [16] [17] However, use of E. coli has limitations including misfolding of eukaryotic proteins, insolubility issues, deposition in inclusion bodies, [18] low secretion efficiency, secretion to periplasmic space.

Streptomyces offers potential advantages including superior secretion mechanisms, higher yields, a simpler end-product purification process, making Streptomyces an attractive alternative to E. coli and Bacillus subtilis . [18]

Streptomyces coelicolor , Streptomyces avermitilis , Streptomyces griseus , and Saccharopolyspora erythraea , are capable of secondary metabolite production. Streptomyces coelicolor has shown useful for the heterologous expression of proteins. Methods like "ribosome engineering" have been used to achieve 180-fold higher yields with S. coelicolor. [19]

Other

StreptomeDB, a directory of Streptomyces isolates, contains over 2400 compounds isolated from more than 1900 strains. [20] [21] Streptomyces hygroscopicus and Streptomyces viridochromeogenes produce the herbicide bialaphos. Expansion of Streptomyces screenings have included endophytes, extremophiles, and marine varieties.[ citation needed ]

A recent screening of TCM extracts revealed a Streptomyces that produces a number of antitubercular pluramycins. [22] Wailupemycins are bio-active pyrones isolated from marine Streptomyces . [23]

Mayamycin has been shown to have cytotoxic properties. [24] [25]

Germicidin are a group of four compounds that act as autoregulatory inhibitors of spore germination. [26] [27]

See also

Related Research Articles

<span class="mw-page-title-main">Myxobacteria</span> Order of bacteria

The myxobacteria are a group of bacteria that predominantly live in the soil and feed on insoluble organic substances. The myxobacteria have very large genomes relative to other bacteria, e.g. 9–10 million nucleotides except for Anaeromyxobacter and Vulgatibacter. One species of myxobacteria, Minicystis rosea, has the largest known bacterial genome with over 16 million nucleotides. The second largest is another myxobacteria Sorangium cellulosum.

<span class="mw-page-title-main">Neomycin</span> Type of antibiotic

Neomycin is an aminoglycoside antibiotic that displays bactericidal activity against gram-negative aerobic bacilli and some anaerobic bacilli where resistance has not yet arisen. It is generally not effective against gram-positive bacilli and anaerobic gram-negative bacilli. Neomycin comes in oral and topical formulations, including creams, ointments, and eyedrops. Neomycin belongs to the aminoglycoside class of antibiotics that contain two or more amino sugars connected by glycosidic bonds.

<i>Streptomyces</i> Genus of bacteria

Streptomyces is the largest genus of Actinomycetota, and the type genus of the family Streptomycetaceae. Over 700 species of Streptomyces bacteria have been described. As with the other Actinomycetota, streptomycetes are gram-positive, and have very large genomes with high GC content. Found predominantly in soil and decaying vegetation, most streptomycetes produce spores, and are noted for their distinct "earthy" odor that results from production of a volatile metabolite, geosmin. Different strains of the same species may colonize very diverse environments.

In organic chemistry, polyketides are a class of natural products derived from a precursor molecule consisting of a chain of alternating ketone and methylene groups: [−C(=O)−CH2−]n. First studied in the early 20th century, discovery, biosynthesis, and application of polyketides has evolved. It is a large and diverse group of secondary metabolites caused by its complex biosynthesis which resembles that of fatty acid synthesis. Because of this diversity, polyketides can have various medicinal, agricultural, and industrial applications. Many polyketides are medicinal or exhibit acute toxicity. Biotechnology has enabled discovery of more naturally-occurring polyketides and evolution of new polyketides with novel or improved bioactivity.

<span class="mw-page-title-main">Efflux (microbiology)</span> Protein complexes that move compounds, generally toxic, out of bacterial cells

In microbiology, efflux is the moving of a variety of different compounds out of cells, such as antibiotics, heavy metals, organic pollutants, plant-produced compounds, quorum sensing signals, bacterial metabolites and neurotransmitters. All microorganisms, with a few exceptions, have highly conserved DNA sequences in their genome that encode efflux pumps. Efflux pumps actively move substances out of a microorganism, in a process known as active efflux, which is a vital part of xenobiotic metabolism. This active efflux mechanism is responsible for various types of resistance to bacterial pathogens within bacterial species - the most concerning being antibiotic resistance because microorganisms can have adapted efflux pumps to divert toxins out of the cytoplasm and into extracellular media.

<span class="mw-page-title-main">Avermectin</span> Drugs to treat parasitic worms and insect pests

The avermectins are a series of drugs and pesticides used to treat parasitic worm infestations and to reduce insect pests. They are a group of 16-membered macrocyclic lactone derivatives with potent anthelmintic and insecticidal properties. These naturally occurring compounds are generated as fermentation products by Streptomyces avermitilis, a soil actinomycete. Eight different avermectins were isolated in four pairs of homologue compounds, with a major (a-component) and minor (b-component) component usually in ratios of 80:20 to 90:10. Avermectin B1, a mixture of B1a and B1b, is the drug and pesticide abamectin. Other anthelmintics derived from the avermectins include ivermectin, selamectin, doramectin, eprinomectin.

<span class="mw-page-title-main">Fosfomycin</span> Chemical compound

Fosfomycin, sold under the brand name Monurol among others, is an antibiotic primarily used to treat lower urinary tract infections. It is not indicated for kidney infections. Occasionally it is used for prostate infections. It is generally taken by mouth.

<span class="mw-page-title-main">Biosynthesis of doxorubicin</span>

Doxorubicin (DXR) is a 14-hydroxylated version of daunorubicin, the immediate precursor of DXR in its biosynthetic pathway. Daunorubicin is more abundantly found as a natural product because it is produced by a number of different wild type strains of streptomyces. In contrast, only one known non-wild type species, streptomyces peucetius subspecies caesius ATCC 27952, was initially found to be capable of producing the more widely used doxorubicin. This strain was created by Arcamone et al. in 1969 by mutating a strain producing daunorubicin, but not DXR, at least in detectable quantities. Subsequently, Hutchinson's group showed that under special environmental conditions, or by the introduction of genetic modifications, other strains of streptomyces can produce doxorubicin. His group has also cloned many of the genes required for DXR production, although not all of them have been fully characterized. In 1996, Strohl's group discovered, isolated and characterized dox A, the gene encoding the enzyme that converts daunorubicin into DXR. By 1999, they produced recombinant Dox A, a Cytochrome P450 oxidase, and found that it catalyzes multiple steps in DXR biosynthesis, including steps leading to daunorubicin. This was significant because it became clear that all daunorubicin producing strains have the necessary genes to produce DXR, the much more therapeutically important of the two. Hutchinson's group went on to develop methods to improve the yield of DXR, from the fermentation process used in its commercial production, not only by introducing Dox A encoding plasmids, but also by introducing mutations to deactivate enzymes that shunt DXR precursors to less useful products, for example baumycin-like glycosides. Some triple mutants, that also over-expressed Dox A, were able to double the yield of DXR. This is of more than academic interest because at that time DXR cost about $1.37 million per kg and current production in 1999 was 225 kg per annum. More efficient production techniques have brought the price down to $1.1 million per kg for the non-liposomal formulation. Although DXR can be produced semi-synthetically from daunorubicin, the process involves electrophilic bromination and multiple steps and the yield is poor. Since daunorubicin is produced by fermentation, it would be ideal if the bacteria could complete DXR synthesis more effectively.

<span class="mw-page-title-main">Aminocoumarin</span> Class of antibiotic chemical compounds

Aminocoumarin is a class of antibiotics that act by an inhibition of the DNA gyrase enzyme involved in the cell division in bacteria. They are derived from Streptomyces species, whose best-known representative – Streptomyces coelicolor – was completely sequenced in 2002. The aminocoumarin antibiotics include:

In enzymology, a [acyl-carrier-protein] S-malonyltransferase is an enzyme that catalyzes the chemical reaction

Blasticidin S is an antibiotic that is used in biology research for selecting cells in cell culture. Cells of interest can express the blasticidin resistance genes BSD or bsr, and can then survive treatment with the antibiotic. Blasticidin S is a nucleoside analogue antibiotic, resembling the nucleoside cytidine. Blasticidin works against human cells, fungi, and bacteria, all by disrupting protein translation. It was originally described by Japanese researchers in the 1950s seeking antibiotics for rice blast fungus.

<i>Streptomyces griseus</i> Species of bacterium

Streptomyces griseus is a species of bacteria in the genus Streptomyces commonly found in soil. A few strains have been also reported from deep-sea sediments. It is a Gram-positive bacterium with high GC content. Along with most other streptomycetes, S. griseus strains are well known producers of antibiotics and other such commercially significant secondary metabolites. These strains are known to be producers of 32 different structural types of bioactive compounds. Streptomycin, the first antibiotic ever reported from a bacterium, comes from strains of S. griseus. Recently, the whole genome sequence of one of its strains had been completed.

<span class="mw-page-title-main">Actinorhodin</span> Chemical compound

Actinorhodin is a benzoisochromanequinone dimer polyketide antibiotic produced by Streptomyces coelicolor. The gene cluster responsible for actinorhodin production contains the biosynthetic enzymes and genes responsible for export of the antibiotic. The antibiotic also has the effect of being a pH indicator due to its pH-dependent color change.

Streptomyces avermitilis is a species of bacteria in the genus Streptomyces. This bacterium was discovered by Satoshi Ōmura in Shizuoka Prefecture, Japan.

<span class="mw-page-title-main">Germicidin</span> Chemical compound

Germicidins are a groups of natural products arising from Streptomyces species that acts as autoregulatory inhibitor of spore germination. In Streptomyces viriochromogenes, low concentrations inhibit germination of its own arthrospores, and higher concentrations inhibit porcine Na+/K+ -activated ATPase. Inhibitory effects on germination are also observed when germicidin from Streptomyces is applied to Lepidium sativum. Germicidins and other natural products present potential use as pharmaceuticals, and in this case, those with possible antibiotic or antifungal activity.

<span class="mw-page-title-main">Carbomycin</span> Chemical compound

Carbomycin, also known as magnamycin, is a colorless, optically active crystalline macrolide antibiotic with the molecular formula C42H67N O16. It is derived from the bacterium Streptomyces halstedii and active in inhibiting the growth of Gram-positive bacteria and "certain Mycoplasma strains." Its structure was first proposed by Robert Woodward in 1957 and was subsequently corrected in 1965.

Spectinabilin is a nitrophenyl-substituted polyketide metabolite. It was first isolated from crude streptovaricin complex produced by Streptomyces spectabilis and presented at the 13th Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington, D.C. in September 1973. Spectinabilin is a biologically active compound, exhibiting both antimalarial and antiviral activity.

Streptomyces albidoflavus is a bacterium species from the genus of Streptomyces which has been isolated from soil from Poland. Streptomyces albidoflavus produces dibutyl phthalate and streptothricins.

Streptomyces arenae is a bacterium species from the genus Streptomyces which has been isolated from soil from Illinois in the United States. Streptomyces arenae produces pentalenolactone, 2,5-dihydrophenylalanine, naphthocyclinone and arenaemycine.

<span class="mw-page-title-main">Tetracenomycin C</span> Chemical compound

Tetracenomycin C is an antitumor anthracycline-like antibiotic produced by Streptomyces glaucescens GLA.0. The pale-yellow antibiotic is active against some gram-positive bacteria, especially against streptomycetes. Gram-negative bacteria and fungi are not inhibited. In considering the differences of biological activity and the functional groups of the molecule, tetracenomycin C is not a member of the tetracycline or anthracyclinone group of antibiotics. Tetracenomycin C is notable for its broad activity against actinomycetes. As in other anthracycline antibiotics, the framework is synthesized by a polyketide synthase and subsequently modified by other enzymes.

References

  1. Watve MG, Tickoo R, Jog MM, Bhole BD (November 2001). "How many antibiotics are produced by the genus Streptomyces?". Arch. Microbiol. 176 (5): 386–90. Bibcode:2001ArMic.176..386W. doi:10.1007/s002030100345. PMID   11702082. S2CID   603765.
  2. Schrey SD, et al. (2012). "Production of fungal and bacterial growth modulating secondary metabolites is widespread among mycorrhiza-associated streptomycetes". BMC Microbiology. 12 (1): 164. doi: 10.1186/1471-2180-12-164 . PMC   3487804 . PMID   22852578.
  3. Akagawa H, Okanishi M, Umezawa H (1975). "A Plasmid Involved in Chloramphenicol Production in Streptomyces venezuelae: Evidence from Genetic Mapping". Journal of General Microbiology. 90 (2): 336–46. doi: 10.1099/00221287-90-2-336 . PMID   1194895.
  4. Miao V (2005). "Daptomycin biosynthesis in Streptomyces roseosporus: Cloning and analysis of the gene cluster and revision of peptide stereochemistry". Microbiology. 151 (5): 1507–23. doi: 10.1099/mic.0.27757-0 . PMID   15870461.
  5. Woodyer RD, Shao Z, Thomas PM, et al. (November 2006). "Heterologous production of fosfomycin and identification of the minimal biosynthetic gene cluster". Chemistry & Biology. 13 (11): 1171–82. doi:10.1016/j.chembiol.2006.09.007. PMID   17113999.
  6. Peschke U, Schmidt H, Zhang H, Piepersberg W (1995). "Molecular characterization of the lincomycin-production gene cluster of Streptomyces lincolnensis 78-11". Molecular Microbiology. 16 (6): 1137–56. doi:10.1111/j.1365-2958.1995.tb02338.x. PMID   8577249. S2CID   45162659.
  7. Howard T. Dulmage (March 1953). "The Production of Neomycin by Streptomyces fradiae in Synthetic Media". Applied Microbiology. 1 (2): 103–106. doi:10.1128/AEM.1.2.103-106.1953. PMC   1056872 . PMID   13031516.
  8. L. Sankaran, Burton M. Pogell (1975-12-01). "Biosynthesis of Puromycin in Streptomyces alboniger: Regulation and Properties of O-Demethylpuromycin O-Methyltransferase". Antimicrobial Agents and Chemotherapy. 8 (6): 721–32. doi:10.1128/AAC.8.6.721. PMC   429454 . PMID   1211926.
  9. Fernandes PB, Vojtko CM, Bower RR, Weisz J (1984). "Spenolimycin, a new spectinomycin-type antibiotic. III. Biological properties". The Journal of Antibiotics. 37 (12): 1525–1527. doi: 10.7164/antibiotics.37.1525 . PMID   6241193.
  10. Distler J, Ebert A, Mansouri K, Pissowotzki K, Stockmann M, Piepersberg W (1987). "Gene cluster for streptomycin biosynthesis inStreptomyces griseus: Nucleotide sequence of three genes and analysis of transcriptional activity". Nucleic Acids Research. 15 (19): 8041–56. doi:10.1093/nar/15.19.8041. PMC   306325 . PMID   3118332.
  11. Dr. Mark Nelson, Robert A. Greenwald, Wolfgang Hillen, Mark L. Nelson (2001). Tetracyclines in biology, chemistry and medicine. Birkhäuser. pp. 8–. ISBN   978-3-7643-6282-9 . Retrieved 17 January 2012.
  12. Maskey RP, Fotso S, Sevvana M, Usón I, Grün-Wollny I, Laatsch H (2006). "Kettapeptin: Isolation, structure elucidation and activity of a new hexadepsipeptide antibiotic from a terrestrial Streptomyces sp". The Journal of Antibiotics. 59 (5): 309–14. doi: 10.1038/ja.2006.44 . PMID   16883782.
  13. Kim HY, Kim JD, Hong JS, Ham JH, Kim BS (2013). "Identification of antifungal niphimycin from Streptomyces sp. KP6107 by screening based on adenylate kinase assay". Journal of Basic Microbiology. 53 (7): 581–9. doi:10.1002/jobm.201200045. PMID   22915202. S2CID   7724547.
  14. Holmes TC, May AE, Zaleta-Rivera K, Ruby JG, Skewes-Cox P, Fischbach MA, Derisi JL, Iwatsuki M, Ōmura S, Khosla C (2012). "Molecular insights into the biosynthesis of guadinomine: A type III secretion system inhibitor". Journal of the American Chemical Society. 134 (42): 17797–806. doi:10.1021/ja308622d. PMC   3483642 . PMID   23030602.
  15. Bauvois B, Dauzonne, D (January 2006). "Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: Chemistry, biological evaluations, and therapeutic prospects". Medicinal Research Reviews. 26 (1): 88–130. doi:10.1002/med.20044. PMC   7168514 . PMID   16216010.
  16. Brawner M, Poste G, Rosenberg M, Westpheling J (1991). "Streptomyces: a host for heterologous gene expression". Curr Opin Biotechnol. 2 (5): 674–81. doi:10.1016/0958-1669(91)90033-2. PMID   1367716.
  17. Payne G, DelaCruz N, Coppella S (1990). "Improved production of heterologous protein from Streptomyces lividans". Appl Microbiol Biotechnol. 33 (4): 395–400. doi:10.1007/BF00176653. PMID   1369282. S2CID   19287805.
  18. 1 2 Binnie C, Cossar J, Stewart D (1997). "Heterologous biopharmaceutical protein expression in Streptomyces". Trends Biotechnol. 15 (8): 315–20. doi:10.1016/S0167-7799(97)01062-7. PMID   9263479.
  19. Wang G, Hosaka T, Ochi K (2008). "Dramatic activation of antibiotic production in Streptomyces coelicolor by cumulative drug resistance mutations". Appl Environ Microbiol. 74 (9): 2834–40. Bibcode:2008ApEnM..74.2834W. doi:10.1128/AEM.02800-07. PMC   2394871 . PMID   18310410.
  20. Lucas X, Senger C, Erxleben A, Grüning BA, Döring K, Mosch J, et al. (2013). "StreptomeDB: a resource for natural compounds isolated from Streptomyces species". Nucleic Acids Res. 41 (Database issue): D1130–6. doi:10.1093/nar/gks1253. PMC   3531085 . PMID   23193280.
  21. "| Pharmaceutical Bioinformatics". 2 November 2018.
  22. Liu M, Abdel-Mageed WM, Ren B, He W, Huang P, Li X, et al. (2014). "Endophytic Streptomyces sp. Y3111 from traditional Chinese medicine produced antitubercular pluramycins". Appl Microbiol Biotechnol. 98 (3): 1077–85. doi:10.1007/s00253-013-5335-6. PMID   24190497. S2CID   15866711.
  23. Kalaitzis JA (2013). "Discovery, Biosynthesis, and Rational Engineering of Novel Enterocin and Wailupemycin Polyketide Analogues". Metabolomics Tools for Natural Product Discovery. Methods in Molecular Biology. Vol. 1055. pp. 171–189. doi:10.1007/978-1-62703-577-4_13. ISBN   978-1-62703-576-7. PMID   23963911.
  24. Bo ST, Xu ZF, Yang L, Cheng P, Tan RX, Jiao RH, Ge HM (June 2018). "Structure and biosynthesis of mayamycin B, a new polyketide with antibacterial activity from Streptomyces sp. 120454". The Journal of Antibiotics. 71 (6): 601–605. doi:10.1038/s41429-018-0039-x. ISSN   1881-1469. PMID   29515228. S2CID   3720406.
  25. Schneemann I, Kajahn I, Ohlendorf B, Zinecker H, Erhard A, Nagel K, Wiese J, Imhoff JF (2010). "Mayamycin, a cytotoxic polyketide from a Streptomyces strain isolated from the marine sponge Halichondria panicea". Journal of Natural Products. 73 (7): 1309–12. doi:10.1021/np100135b. PMID   20545334.
  26. Aoki Y, Matsumoto, D, Kawaide, H, Natsume, M (September 2011). "Physiological role of germicidins in spore germination and hyphal elongation in Streptomyces coelicolor A3(2)". The Journal of Antibiotics. 64 (9): 607–11. doi: 10.1038/ja.2011.59 . PMID   21792209.
  27. Petersen F, Zähner, H, Metzger, JW, Freund, S, Hummel, RP (July 1993). "Germicidin, an autoregulative germination inhibitor of Streptomyces viridochromogenes NRRL B-1551". The Journal of Antibiotics. 46 (7): 1126–38. doi: 10.7164/antibiotics.46.1126 . PMID   8360109.